Summary
Brilacidin is a novel host defense protein being studied for the treatment of community-acquired skin and soft tissue infections. A phase 2b trial shows that a single-dose injection of brilacidin is as effective as a 7-day dose of daptomycin in treating acute bacterial skin and skin structure infections associated with Staphylococcus aureus.
- acute bacterial skin and skin structure infections
- brilacidin, methicillin-resistant Staphylococcus aureus
- MRSA
- daptomycin
- infectious diseases clinical trials
- bacterial infections
- © 2015 SAGE Publications
Tools
Table of contents
Cited By...
- No citing articles found.